2nd SOHO Italian Conference

February 2, 2021

2nd SOHO Italian Conference

H. Kantarjian

2nd SOHO Italian Conference

H. Kantarjian

2nd SOHO Italian Conference

H. Kantarjian

2nd SOHO Italian Conference

H. Kantarjian

2nd SOHO Italian Conference

E. Abruzzese

2nd SOHO Italian Conference

2nd SOHO Italian Conference

2nd SOHO Italian Conference

2nd SOHO Italian Conference

2nd SOHO Italian Conference

F. Buccisano

2nd SOHO Italian Conference

2nd SOHO Italian Conference

S. Galimberti

2nd SOHO Italian Conference

I. Iacobucci

2nd SOHO Italian Conference

2nd SOHO Italian Conference

C. Papayannidis

2nd SOHO Italian Conference

2nd SOHO Italian Conference

A. Ghelli Luserna Di Rora

2nd SOHO Italian Conference

2nd SOHO Italian Conference

G. Martinelli

2nd SOHO Italian Conference

C. Cerchione

2nd SOHO Italian Conference

C. Cerchione

2nd SOHO Italian Conference

A. Ferrajoli

2nd SOHO Italian Conference

A. de la Fuente

2nd SOHO Italian Conference

M. Konopleva

2nd SOHO Italian Conference

2nd SOHO Italian Conference

S. Verstovsek

2nd SOHO Italian Conference

2nd SOHO Italian Conference

2nd SOHO Italian Conference

2nd SOHO Italian Conference

2nd SOHO Italian Conference

2nd SOHO Italian Conference

G. Garcia-Manero

2nd SOHO Italian Conference

2nd SOHO Italian Conference

Login

Login

Join VuMedi

2nd SOHO Italian Conference

MD Anderson Future Directions in AML: Efficacy of FLT3 / IDH Inhibitors and New Targeted Therapy Combos

Making the First Chance Count: Manuel

Moving Forward in Stage III/IV Classical Hodgkin Lymphoma

MRD & ALL Management: What Role Does It Play in AlloHSCT Setting?

How I Treat AML at MD Anderson: ATRA & GO Combos, Sequential HD Chem…

MD Anderson Future Directions in AML: Efficacy of FLT3 / IDH Inhibit…

How I Treat ALL at MD Anderson: What Hyper-CVAD Combinations Showed …

MD Anderson Future Directions in ALL: How Effective Are New Blina/In…

TFR and CML: Why Is TFR Important? What Happens After? Why Is It Dif…

TFR in CML: What Are the Influencing Factors? Do Patients Lose MR Af…

How I Treat Frontline CML: What Are the Differences in ELTS vs. Soka…

Post-SCT Maintenance in AML: What Is the Role of Hypomethylating Age…

Allogenic Transplant in AML: How Does ASCT Compare to Chemo in Older…

MRD Assessment in Frontline AML: What Are the Characteristics of Dif…

Prognostic Relevance of BPDCN-Like Phenotype in Newly Diagnosed AML:…

Pro-Apoptotic Pathways in AML: How Does Venetoclax Work in Combinati…

Genomic Sequencing in AML and MDS: How Can We Define Subtypes and Mu…

Novel mAbs in ALL: Is Ino Better than SoC? What Is the MRD-Negativit…

mAbs in ALL: Does Blinatumomab Prolong Survival in R/R Ph+/- Disease…

Cell Morphology in Acute Leukemias & Hematologic Malignancies: Diffe…

Synthetic Lethality Against ALL: How Often Is the Expression of DDR-…

2020 SOHO Update on R/R ALL: Is CD19-Targeted CAR-T Beneficial for O…

2020 SOHO Updates on ALL: Does Ponatinib+Steroids Help Induce CHR in…

2020 SOHO Updates on Newly Diagnosed AML: Does CPX-351 Increase OS a…

2020 SOHO Updates on AML: Is Targeting CAMDR a New Frontier? Can E-S…

MD Anderson State of the Art in CLL Treatment: What Is Changing and …

2020 SOHO Updates on Newly Diagnosed AML: What Is the ORR With Aza v…

2020 SOHO Update on Ph-Like ALL: How Important Are Genomic Alteratio…

2020 SOHO Update on AML in Older Patients at MD Anderson: Therapy In…

2020 SOHO Update on MPN: Ruxolitinib vs. BAT in ET, Ruxolitinib in P…

2020 SOHO Update on Diagnostic Approaches to Ph-Like B-ALL: CRLF2 De…

2020 SOHO Update on FLT3+ AML: What Are the Novel FLT3 Inhibitors? H…

2020 SOHO Update on Immunotherapy in AML: Gemtuzumab Ozogamicin Plus…

How I Manage CML at MD Anderson in 2020: How Effective & Safe Is Das…

2020 SOHO Update on Frontline Therapy Optimization in ALL: How Effec…

2020 SOHO Update on Frontline MDS: What Is the Role of Genomic Annot…

2020 SOHO Update on Antibodies in AML: Is Gemtuzumab Ozogamicin Effe…

2020 SOHO Update on Maintenance AML: Does It Improve Clinical Outcom…